A Startup Has Been Quietly Pitching Cloned Human Bodies to Transfer Your Brain Into

In a world where the line between science fiction and reality is increasingly blurring, a secretive startup has been quietly pushing the boundaries of what is possible. R3 Bio, a company backed by a billionaire investor, has been working on a project that aims to create non-sentient monkey "organ sacks" as an alternative to animal testing. These structures, which contain all typical organs except the brain, are intended to serve as a source for donor organs and tissues. However, as MIT Technology Review delved deeper into the company's ambitions, it uncovered a far more ambitious goal: the development of entire "brainless clones" of the human body, into which aging or ill individuals could potentially transfer their brains.

Since the mid-1990s, scientists have been captivated by the prospect of cloning animals, with Dolly the sheep becoming the first mammal cloned from an adult cell in 1996. While cloning animal embryos has progressed significantly, transitioning to human cloning has proven far more controversial. Scientists have only managed to generate human embryo models and clone primates from fetal cells, not adult cells like Dolly. Despite these challenges, some have explored the idea of cloning as an alternative to anti-aging technology, a concept that sounds like it was taken straight from a dystopian science fiction novel.

R3 Bio's founders have been working on this ambitious project in secret, aiming to create brainless human clones that could be used as a means of transferring a person's brain. One advantage of this approach is that it circumvents certain moral dilemmas associated with cloning, as the brain would not be developed in the donor body. However, describing the idea as ethically fraught would be a significant understatement.

Despite the controversy surrounding the project, R3 Bio's founder, John Schloendorn, has reportedly pitched the concept as a "close encounter of the third kind" with "Dr. Strangelove" in an interview with Tech Review. The company has since distanced itself from the idea of brainless human clones, stating that Schloendorn "never made any statement regarding human clones."

The idea of transferring a human brain into a cloned body raises numerous ethical questions, including those related to the rights of the cloned individual and the potential for abuse of this technology. Furthermore, the scientific challenges involved in such a project are immense, from the complexities of cloning a human body to the intricacies of transferring a brain and ensuring its survival.

While R3 Bio has not explicitly endorsed the concept of brainless human clones, the company's work on monkey organ sacks has raised concerns about the potential misuse of cloning technology. As the field of cloning continues to evolve, it is crucial for scientists, ethicists, and policymakers to engage in a thorough discussion about the implications of such advancements. The potential benefits of cloning, such as the development of donor organs and tissues, must be carefully weighed against the ethical dilemmas and risks involved.

In the end, the future of cloning and its applications remains uncertain. While R3 Bio's ambitious goals may seem like they were taken straight from a science fiction novel, the reality is that the line between possibility and impossibility is often blurred in the world of scientific innovation. As the company moves forward with its plans for monkey organ sacks, the question of whether brainless human clones will ever become a reality remains to be seen. One thing is clear, however: the potential implications of such advancements are both profound and far-reaching, and the world must be prepared to grapple with the ethical and societal challenges that may arise.